Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm

Chao Wang, Xiaoyong Zhu, Weiwei Feng, Yinhua Yu, Kangjin Jeong, Wei Guo, Yiling Lu, Gordon Mills

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Yes-associated protein (YAP), the central mediator of Hippo pathway, not only regulates a diversity of cellular processes during development but also plays a pivotal role in tumorigenesis. YAP is overexpressed in many types of human cancers with its expression level being associated with patient outcomes. Thus, inhibiting YAP function could provide a novel therapeutic approach. Verteporfin, a photosensitizer, which has been used in photodynamic therapy (PDT), was recently identified as an inhibitor of the interaction of YAP with TEAD, which, in turn, blocks transcriptional activation of targets downstream of YAP. However, the mechanism by which Verteporfin inhibits YAP activity remains to be elucidated. We demonstrate that overexpression of YAP stimulates cell proliferation whereas knocking down YAP or treating cells with Verteporfin inhibited cell proliferation, even in the presence of growth factors. Protoporphyrin IX, another photosensitizer, did not have similar activity demonstrating specificity to Verteporfin. Verteporfin induced sequestration of YAP in cytoplasm through increasing levels of 14-3-3σ, a YAP chaperon protein that retains YAP in cytoplasm and targets it for degradation in the proteosome. Interestingly, while knockdown of YAP had no effect on the ability of Verteporfin to induce 14-3-3σ, p53 is required for this effect of Verteporfin. This provides potential approaches to select patients likely to benefit from Verteporfin.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalAmerican Journal of Cancer Research
Volume6
Issue number1
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Cytoplasm
Proteins
Photosensitizing Agents
verteporfin
Cell Proliferation
Photochemotherapy
Transcriptional Activation
Intercellular Signaling Peptides and Proteins
Carcinogenesis

Keywords

  • 14-3-3σ
  • Endometrial cancer
  • Verteporfin
  • YAP

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. / Wang, Chao; Zhu, Xiaoyong; Feng, Weiwei; Yu, Yinhua; Jeong, Kangjin; Guo, Wei; Lu, Yiling; Mills, Gordon.

In: American Journal of Cancer Research, Vol. 6, No. 1, 01.01.2016, p. 27-37.

Research output: Contribution to journalArticle

Wang, Chao ; Zhu, Xiaoyong ; Feng, Weiwei ; Yu, Yinhua ; Jeong, Kangjin ; Guo, Wei ; Lu, Yiling ; Mills, Gordon. / Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. In: American Journal of Cancer Research. 2016 ; Vol. 6, No. 1. pp. 27-37.
@article{4765065547eb45c2bf6c5e18b8d2a111,
title = "Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm",
abstract = "Yes-associated protein (YAP), the central mediator of Hippo pathway, not only regulates a diversity of cellular processes during development but also plays a pivotal role in tumorigenesis. YAP is overexpressed in many types of human cancers with its expression level being associated with patient outcomes. Thus, inhibiting YAP function could provide a novel therapeutic approach. Verteporfin, a photosensitizer, which has been used in photodynamic therapy (PDT), was recently identified as an inhibitor of the interaction of YAP with TEAD, which, in turn, blocks transcriptional activation of targets downstream of YAP. However, the mechanism by which Verteporfin inhibits YAP activity remains to be elucidated. We demonstrate that overexpression of YAP stimulates cell proliferation whereas knocking down YAP or treating cells with Verteporfin inhibited cell proliferation, even in the presence of growth factors. Protoporphyrin IX, another photosensitizer, did not have similar activity demonstrating specificity to Verteporfin. Verteporfin induced sequestration of YAP in cytoplasm through increasing levels of 14-3-3σ, a YAP chaperon protein that retains YAP in cytoplasm and targets it for degradation in the proteosome. Interestingly, while knockdown of YAP had no effect on the ability of Verteporfin to induce 14-3-3σ, p53 is required for this effect of Verteporfin. This provides potential approaches to select patients likely to benefit from Verteporfin.",
keywords = "14-3-3σ, Endometrial cancer, Verteporfin, YAP",
author = "Chao Wang and Xiaoyong Zhu and Weiwei Feng and Yinhua Yu and Kangjin Jeong and Wei Guo and Yiling Lu and Gordon Mills",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "27--37",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm

AU - Wang, Chao

AU - Zhu, Xiaoyong

AU - Feng, Weiwei

AU - Yu, Yinhua

AU - Jeong, Kangjin

AU - Guo, Wei

AU - Lu, Yiling

AU - Mills, Gordon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Yes-associated protein (YAP), the central mediator of Hippo pathway, not only regulates a diversity of cellular processes during development but also plays a pivotal role in tumorigenesis. YAP is overexpressed in many types of human cancers with its expression level being associated with patient outcomes. Thus, inhibiting YAP function could provide a novel therapeutic approach. Verteporfin, a photosensitizer, which has been used in photodynamic therapy (PDT), was recently identified as an inhibitor of the interaction of YAP with TEAD, which, in turn, blocks transcriptional activation of targets downstream of YAP. However, the mechanism by which Verteporfin inhibits YAP activity remains to be elucidated. We demonstrate that overexpression of YAP stimulates cell proliferation whereas knocking down YAP or treating cells with Verteporfin inhibited cell proliferation, even in the presence of growth factors. Protoporphyrin IX, another photosensitizer, did not have similar activity demonstrating specificity to Verteporfin. Verteporfin induced sequestration of YAP in cytoplasm through increasing levels of 14-3-3σ, a YAP chaperon protein that retains YAP in cytoplasm and targets it for degradation in the proteosome. Interestingly, while knockdown of YAP had no effect on the ability of Verteporfin to induce 14-3-3σ, p53 is required for this effect of Verteporfin. This provides potential approaches to select patients likely to benefit from Verteporfin.

AB - Yes-associated protein (YAP), the central mediator of Hippo pathway, not only regulates a diversity of cellular processes during development but also plays a pivotal role in tumorigenesis. YAP is overexpressed in many types of human cancers with its expression level being associated with patient outcomes. Thus, inhibiting YAP function could provide a novel therapeutic approach. Verteporfin, a photosensitizer, which has been used in photodynamic therapy (PDT), was recently identified as an inhibitor of the interaction of YAP with TEAD, which, in turn, blocks transcriptional activation of targets downstream of YAP. However, the mechanism by which Verteporfin inhibits YAP activity remains to be elucidated. We demonstrate that overexpression of YAP stimulates cell proliferation whereas knocking down YAP or treating cells with Verteporfin inhibited cell proliferation, even in the presence of growth factors. Protoporphyrin IX, another photosensitizer, did not have similar activity demonstrating specificity to Verteporfin. Verteporfin induced sequestration of YAP in cytoplasm through increasing levels of 14-3-3σ, a YAP chaperon protein that retains YAP in cytoplasm and targets it for degradation in the proteosome. Interestingly, while knockdown of YAP had no effect on the ability of Verteporfin to induce 14-3-3σ, p53 is required for this effect of Verteporfin. This provides potential approaches to select patients likely to benefit from Verteporfin.

KW - 14-3-3σ

KW - Endometrial cancer

KW - Verteporfin

KW - YAP

UR - http://www.scopus.com/inward/record.url?scp=84976232067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976232067&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 27

EP - 37

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 1

ER -